Dryen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 26-12-2024
- Paid Up Capital ₹ 0.10 M
as on 26-12-2024
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Revenue -49.23%
(FY 2020)
- Profit -418.00%
(FY 2020)
- Ebitda -184.94%
(FY 2020)
- Net Worth -172.75%
(FY 2020)
- Total Assets -9.95%
(FY 2020)
About Dryen Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hiteshkumar Lapsiwala, Prince Desai, Brijesh Singh, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230GJ2018PTC104212
- Company No.
104212
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2018
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dryen Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Singh  | Managing Director | 21-Nov-2018 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hiteshkumar Lapsiwala | Whole-Time Director | 29-Feb-2020 | Current |
| Prince Desai | Director | 20-Sep-2018 | Current |
| Brijesh Singh | Whole-Time Director | 08-Oct-2018 | Current |
| Chetna Savani | Whole-Time Director | 29-Feb-2020 | Current |
Financial Performance of Dryen Pharmaceuticals.
Dryen Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 49.23% decrease. The company also saw a substantial fall in profitability, with a 418% decrease in profit. The company's net worth observed a substantial decline by a decrease of 172.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dryen Pharmaceuticals?
Unlock access to Dryen Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dryen Pharmaceuticals?
Unlock and access historical data on people associated with Dryen Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dryen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dryen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
